



PRODUCT: **AYVAKIT™ (avapritinib)**

COMPANY: Blueprint Medicines

THERAPEUTIC AREA & INDICATION:
Treatment of gastrointestinal stromal tumor

ABOUT THE PRODUCT

AYVAKIT™ (avapritinib) is a kinase inhibitor approved by the FDA for the treatment of two indications: adults with advanced systemic mastocytosis, including aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm and mast cell leukemia (Limitations of Use: AYVAKIT is not recommended for the treatment of patients with advanced systemic mastocytosis with platelet counts of less than $50 \times 10^9/L$), and adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. For more information, including important prescribing information, visit AYVAKIT.com.